MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Interpace Biosciences DPO Ratio 2011-2026 | IDXG
Annual DPO Ratio Interpace Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.4 | 31.6 | 32.5 | 75 | 76 | 111 | 37.9 | 19.4 | 128 | 82.4 | 15.5 | 6.78 | 12.4 | 12.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 128 | 6.78 | 48.2 |
Quarterly DPO Ratio Interpace Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.6 | 34.4 | 37.3 | - | 36 | 33.6 | 34.3 | - | 33.6 | 35.6 | 31.2 | - | 65.6 | 95.6 | 74.4 | - | 61.8 | 43.2 | 64.5 | - | 79.2 | 107 | 68.8 | - | 88.9 | 142 | 100 | - | 35 | 43 | 25.6 | - | 17.2 | 19 | 70 | - | 115 | 115 | 150 | - | 79.1 | 76.9 | 108 | - | 16.1 | 15.2 | 11.1 | - | 50.7 | 43.6 | 63 | - | 75.9 | 76 | 75 | - | 90.5 | 66.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 150 | 11.1 | 62.3 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Trinity Biotech plc
TRIB
|
163 | $ 0.73 | -1.86 % | $ 61.9 M |  Irlanda |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 29.0 | -3.07 % | $ 316 M |  China |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
104 | $ 1.14 | -2.16 % | $ 1.45 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
106 | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
66.4 | $ 210.56 | -0.33 % | $ 154 B | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 29.41 | -6.17 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 202.21 | -0.11 % | $ 22.4 B | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
67.7 | $ 73.08 | 1.11 % | $ 28.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
43.9 | $ 11.75 | 2.8 % | $ 333 M |  Israel |
 |
CareDx, Inc
CDNA
|
44.2 | $ 18.83 | -5.23 % | $ 1.01 B | USA |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Illumina
ILMN
|
56.3 | $ 117.53 | -2.06 % | $ 18.7 B | USA |
 |
Fulgent Genetics
FLGT
|
34.9 | $ 23.18 | -0.39 % | $ 701 M | USA |
 |
Exact Sciences Corporation
EXAS
|
49.2 | $ 103.45 | 0.15 % | $ 19.5 B | USA |
 |
Lantheus Holdings
LNTH
|
25.3 | $ 74.31 | 1.54 % | $ 5.14 B | USA |
 |
Guardant Health
GH
|
48.6 | $ 103.36 | -2.84 % | $ 13 B | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 99.61 | 1.22 % | $ 8.22 B | Irlanda |
 |
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 169.68 | 3.11 % | $ 8.41 B | USA |
 |
IDEXX Laboratories
IDXX
|
27 | $ 635.6 | 0.77 % | $ 52.4 B | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 166.19 | -1.87 % | $ 28.6 B | USA |
 |
Quidel Corporation
QDEL
|
101 | $ 22.47 | -4.85 % | $ 947 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
33.1 | $ 283.38 | 0.32 % | $ 23.8 B | USA |
 |
Biomerica
BMRA
|
32.4 | $ 2.17 | -2.25 % | $ 4.98 M | USA |
 |
Bioventus
BVS
|
59.2 | $ 8.57 | -0.06 % | $ 537 M | USA |
 |
Medpace Holdings
MEDP
|
13.3 | $ 452.99 | 1.47 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
10.1 | $ 13.65 | 9.64 % | $ 335 M | USA |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 378.44 | 0.14 % | $ 28.4 B |  Schweiz |